Clinical trial NCT00198302: Clinical Trial Comparing Safety and Pharmacokinetics of Standard Antibiotic Therapy, Plus Aurexis® or Placebo, for Treatment of Staphylococcus Aureus Bacteremia (SAB)
Official title: A Phase II, Randomized, Double-blind, Multi-center Clinical Trial Comparing Safety and Pharmacokinetics of Standard Antibiotic Therapy, Plus Aurexis® or Placebo, for Treatment of Staphylococcus Aureus Bacteremia (SAB)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Staphylococcus Aureus Bacteremia
Keywords: staphylococcus aureus
bacteremia
sepsis
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2005-09-20
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Hospitalized patients at least 18 years of age, with Staphylococcus aureus bacteremia (SAB) will be enrolled into the study and receive one dose of Aurexis® intravenously on Study Day 1, and will be followed until Study Day 57. Aurexis is a humanized monoclonal antibody that is designed to combat Staphylococcus aureus.

The purpose of this study is to assess the safety and pharmacokinetics of standard antibiotic therapy, plus Aurexis or Placebo for treatment of (SAB). Additionally, certain tests and measurements will be conducted to preliminarily determine if Aurexis demonstrates any benefit to these patients.


Eligibility criteria: Inclusion Criteria:

* Male or female, age ≥ 18 years old
* Informed consent obtained from subject or legal guardian
* Willing to practice reliable birth control measures during the study period
* Diagnosis of SAB, as evidenced by clinical symptoms and one positive blood culture obtained ≤ 72 hours prior to initiation of study drug infusion

Exclusion Criteria:

* Pregnant or nursing females
* Polymicrobial bacteremia
* Diagnosis of septic shock (refer to APPENDIX B)
* Neutropenia (absolute neutrophil count \< 500/mm³)
* Undergoing any type of dialysis or expected to start dialysis within 30 days
* Moribund clinical condition with a high likelihood of death within 72 hours of randomization
* Received an investigational drug within 30 days of study entry
* Considered unlikely to comply with the study procedures or to return for scheduled post-treatment evaluations

Primary outcomes:
measure: • To evaluate the safety of standard of care, plus a single dose of Aurexis® compared to a single dose of placebo, in subjects with documented SAB
measure: • To evaluate the pharmacokinetics of a single dose of Aurexis® in combination with standard of care in the subjects with SAB
measure: • To evaluate the activity of a single dose of Aurexis® in combination with standard of care, as measured by:
measure: o number of subjects with uncomplicated SAB at baseline who progress to complicated SAB
measure: o number of subjects with microbiologically documented relapse of SAB
measure: o mortality rates
Secondary outcomes:
measure: • To evaluate the effect of a single dose of Aurexis® in combination with standard of care on the:
measure: o proportion of subjects who develop sepsis, severe sepsis, or septic shock
measure: o time to achieve a negative blood culture
measure: o time to defervescence
measure: o mean (and median) number of days in the hospital and ICU
measure: o mean (and median) number of days requiring mechanical ventilation
Other outcomes:
Locations:
Study officials:
affiliation: Inhibitex
name: Seth Hetherington, M.D.
role: STUDY_DIRECTOR
References: